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A diagnosis of Fabry gastrointestinal disease by chance:
a case report
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Fabry disease is an X-linked lysosomal storage disease
caused by a deficiency of a-galactosidase A. This deter-
mines an accumulation of globotriaosylceramide within
lysosomes. The clinical picture is highly variable and
depends on cellular storage deposition. Renal, cardiac and
nervous system are the most frequent organs involved.
Gastrointestinal involvement is also present, associated
with other clinical signs of Fabry disease and sometimes
can be a prominent clinical manifestation. We describe a
Fabry disease case in which gastrointestinal involvement
was the first and the only clinical sign of Fabry disease and
a diagnosis of Fabry disease was made by chance during a
family screening. Enzyme replacement therapy was started
and after 3 months, there was a complete disappearance of
signs. Eur J Gastroenterol Hepatol 19:163–165 c 2007
Lippincott Williams & Wilkins.
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Introduction
Fabry disease (FD) is a lysosomal storage disorder caused
by a mutation affecting the a-galactosidase A (GLA)
gene, mapped at locus Xq22 of the long arm of the X
chromosome, that encodes the a-galactosidase A (GAL A)
enzyme. This change determines a total or partial
deficiency of GAL A enzyme that results in a pathologic
metabolism of glycosfingolipids and a progressive accu-
mulation of globotriaosylceramide (Gb3) within lyso-
somes. The clinical picture is due to the involvement
of cells of different organs by the Gb3 accumulation.
Renal involvement (proteinuria and progressive renal
failure), cardiac disease (hypertrophic cardiomyopathy)
and neurological involvement (stroke in young people)
are the most frequent and common features. As the
intracellular accumulation of Gb3 can be found in
any tissue, the clinical involvement will be extremely
variable and a number of other signs and symptoms
will be present (fever, pain on lower limbs, heat
intolerance) [1]. Gastrointestinal involvement has been
also described with bouts of pain, diarrhoea and
constipation [2,3].
We describe a case of a young man with bouts of
abdominal pain and constipation, in whom Crohn’s
disease was suspected. The only significant clinical
manifestation of FD was, actually, gastrointestinal symp-
toms. The diagnosis was made by chance (during a family
biochemical and molecular analysis) and the enzyme
replacement therapy (ERT) was associated with a
complete recovery.
Case report
In June 2004, a diagnosis of FD was made in a 26-year-old
man (II: 2, Fig. 1). He had started regular haemodialytic
treatment some weeks before because of a severe renal
involvement with kidney failure (stage 5 K/DOQI CKD).
No other clinical signs and or symptoms of FD were
present except heat intolerance. In order to exclude a FD
in our Unit, a screening of GAL A enzyme, on blood spot,
was performed in all patients in haemodialytic treatment
with unknown diagnosis. During such a screening, a-GAL
A plasma level was almost absent in this patient and this
result was confirmed also on leukocytes (2.2 nmol/mg/h;
n.v. > 46). On the basis of this, the entire GLA gene
encoding region and the exon/intron boundaries were
sequenced and a new c1079G>A nucleotide transition
that leads to a new G360D amino acid change was
identified.
Afterwards (September 2004), his family (mother and two
brothers, Fig. 1) was investigated for a a-GAL deficiency.
For his older brother (II:1), the anamnesis was negative,
whereas his younger brother (II:3) reported a long history of
gastrointestinal symptoms with recurrent bouts of abdom-
inal pain associated with both constipation and diarrhoea.
A few months before our diagnosis (April 2004), he was
admitted to a University Hospital because of an episode of
fever associated with pain in the lower limbs. The routinely
performed laboratory analyses were in the normal range:
serum creatinine 79.5mmol/l, blood urea nitrogen
10.3mmol/l, uric acid 362.8mmol/l, glucose 3.6mmol/l,
cholesterol 3.57mmol/l, triglycerides 0.994mmol/l, red
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blood cells 4780.000 1012/l, Hb 13.9 g/l, white blood cells
8.240 109/l3, platelets 304 109/l. A mild increase of:
erythrocyte sedimentation rate (ESR) 52mm/h, C-reactive
protein (CPR) 5mg/dl (n.v. <1mg/l), b-2 serum micro-
globulin 2.7mg/l (n.v. <2.7mg/l) was seen. Chest radio-
graph, ECG, renal and liver ultrasound and auto-antibodies
and infectious tests were negative. An echocardiography was
normal. Rheumatology and haematology consultancies were
inconclusive.
To investigate gastrointestinal symptoms, a colonoscopy
was carried out which displayed a flat adenoma and some
small areas of hyperaemia. Notwithstanding a nonspecific
histological examination, Crohn’s disease was suspected.
Meanwhile, the genetic investigation (September 2004)
carried out in this family led to the identification of the
c1079G>A (G360D) genetic lesion in his mother (I:2)
at heterozygous level, and at hemizygous level in the
brother (II:3) with gastrointestinal symptoms, whereas
the analysis in the other brother (II:1) was negative.
Alpha-GAL A enzyme activity in leukocytes was 0.9 nmol/
mg/h in the patient with only gastrointestinal symptoms
(II:3); 40% of normal control in his mother. On the basis
of that, a diagnosis of FD was made in this family (Fig. 1).
In January–March 2005, the patient (II:3) with gastro-
intestinal symptoms, was admitted at our hospital and
carefully investigated for FD. No other clinical symptoms
and or signs were found (kidney, heart, etc.), in particular,
inflammation indexes (ESR, CPR, b2) were within the
normal range. A gastrointestinal screening, a radiograph
enteroclysis of the colon and an endoscopy were all
negative (Figs 2 and 3). He complained only of a mild
heat intolerance. Then, ERT was started (agalsidase-a
0.2mg/kg/15 days) and after 3 months he referred a
significant improvement of his bowel functions: the bouts
of diarrhoea and constipation had disappeared.
Discussion
This case showed the importance of including a suspect
of a FD in the differential diagnosis of gastrointestinal
disorders. Indeed, nonspecific gastrointestinal symptoms
can be present in FD patients and include abdominal
pain, diarrhoea, constipation, bloating, vomiting and poor
weight gain. In a review, based on data collected from all
Europe (Fabry Outcome Survey, FOS) and regarding a
collection of 366 FD patients, gastrointestinal symptoms
were present in 57% of males and 47% of females with
FD: the most frequent symptoms were abdominal pain
and diarrhoea [4]. Histological studies have demonstrated
that gastrointestinal involvement in FD is very likely due
to Gb3 accumulation in vegetative neurons of Meissner’s
plexus, in endothelial cells of vessels and in smooth
muscle cells, compromising mesenteric circulation
[3,5].
On the other hand, sometimes FD is concomitant with








Pedigree of the family in study.
Fig. 2
Normal ileum. An aggregated lymphatic nodule presenting in mucosa
and submucosa (haematoxylin–eosin stain, magnification 100).
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the presence of FD in an 11-year-old girl affected by
coeliac disease. Diagnosis of FD was made with a renal
biopsy carried out because of proteinuria. In addition, the
coexistence of FD and Crohn’s disease has been recently
described [7] in a 30-year-old woman. In this case, a
hereditary nephropathy was suspected because her
mother died in end-stage renal failure and her brother
also was affected by a chronic renal failure. Laboratory
and genetic investigation displayed GAL A enzyme
deficiency in this family.
In our case, the diagnosis was made by chance during a
biochemical and molecular analysis family screening for
FD. Crohn’s disease was suspected in our patient because
gastrointestinal symptoms were associated with a mild
increase of inflammation (CPR, ESR). Small bowel
radiograph and histological study of intestinal mucosa,
however, did not display any lesions consistent with
Crohn’s disease like stenosis of abdominal lumen or
granulomas and changes in the architecture of glands.
Regarding FD, two clues, although nonspecific for FD,
were present in the clinical history: the episode of
unknown fever associated with pain in lower limbs and
the existence of a brother with renal failure.
The start of ERT was followed, after 3 months, by a
complete recovery and all gastrointestinal symptoms
disappeared. A significant improvement of gastrointest-
inal diseases with ERT is shared in some experiences.
Dehout et al. [8] describes a reduction of severity and
frequency of abdominal pain after 6 months of ERT in a
group of FD patients. Banikazemi et al. [9] reported
marked improvements of gastrointestinal symptoms after
6–7 months of ERT and the patients were able to
interrupt their gastrointestinal medications. It can be
interesting to point out that, in our case, clinical
improvement was observed after only 3 months of ERT.
That might be due to a milder cellular accumulation of
Gb3 or a particular sensitivity of our patient to ERT. On
the other hand, a very rapid improvement of gastro-
intestinal symptoms, following the first few infusions of
ERT, has been already described by Hoffmann et al. [10]
in a patient with a typical long story of FD. Actually, the
reasons for which some patients have these prompt
responses to ERT remain still unclear [10].
This case demonstrates how diagnosis of FD can be an
easily missed diagnosis because a very wide range of
symptoms may be present. Moreover, often clinical
features are nonspecific, like bouts of intestinal problems
and the diagnosis of FD is possible only taking it into
account in a differential diagnosis. Moreover, our report
confirms that ERT is able to correct the clinical picture of
gastrointestinal disorder completely. We also would like to
stress the interfamilial clinical heterogeneity in this
family.
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Fig. 3
Large bowel: a normal structure is evident (haematoxylin–eosin stain,
magnification 200).
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